• Autoimmune Disorders Conference, all presentations

    Original Date: March 17-18, 2018

    This discounted package includes all of the individual presentations from the conference.

    12.0 CEUs (including 1.5 pharmacy, and 2.0 ethics) approved by OBNM

  • Celiac Disease - Common and Underdiagnosed: research update

    Presenter: Lisa Shaver, ND, LAc
    Original Date: March 17, 2018

    Celiac disease made a splash with the gluten-free diet craze. Gluten is now almost a household word, however celiac disease continues to be underdiagnosed in the US and around most of the world. Celiac disease is a common condition effecting 1% of the population, yet in the United States we have only diagnosed an estimated 15%-20% of all celiacs.
    Research is robust on celiac disease and the complexities continue to be revealed. Dr Shaver will guide you on an update of the recent research on celiac disease with brief mention of the non-autoimmune disorder of non-celiac gluten sensitivity, in the areas of pediatrics and adolescents, Research on pharmaceutical treatment advancements in celiac disease will be discussed.

    1.5 general CEUs approved by OBNM

  • qPCR Analysis of the GI Microbiome and Naturopathic Management of Autoimmune Disease

    Presenter: David M. Brady, ND, DC, CCN, DACBN, IFMCP
    Original Date: March 17. 2018

    Autoimmune disease is growing at epidemic proportions. Standard interventions are based on symptom control and immune suppression. This presentation with review a proactive integrative, systems biology, approach for the naturopath to address disease prediction, prevention and treatment, including various evidence-based modalities. The role of the GI microbiota, food immune reactions, stealth infections and molecular mimicry in autoimmune disease pathogenesis will be explored along with how these may serve as leverage points for naturopathic clinical interventions. The hygiene hypothesis and changes in early environmental antigen exposure will also be explored. New opportunities for proactive screening for at-risk subjects for autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, diabetes, multiple sclerosis, lupus, and others using qPCR molecular methods of assessing the GI microbiota, as well as emerging predictive antibody testing, will also be reviewed and discussed from the perspective of the naturopathic doctor.

    1.5 general CEUs approved by OBNM
  • Fibromyalgia and Global Pain Syndromes: The REAL Story!

    Presenter: David M. Brady, ND, DC, CCN, DACBN, IFMCP
    Original Date: March 17, 2018

    Research suggests that “classic” fibromyalgia (FMS) is a central pain processing disorder and does not appear to be a peripheral somatic disorder. Dr. Brady will emphasize the concept that this central-mediated disorder is strongly associated with psychological disorders, including trauma and abuse history, depression, anxiety, irritable bowel syndrome, and sleep disorder. Common mechanisms in-play regarding these concomitant issues and global pain will be fully explored and accurate differential diagnostic and comprehensive naturopathic therapeutic strategies will be discussed in-detail. The concept of “pseudo” or “false” fibromyalgia diagnostic labels will also be discussed, to include various organic and functional medical conditions, as well as somatic musculoskeletal conditions, which confound the accurate diagnosis of “classic” FMS will also be presented. Natural and pharmacological interventions options will be presented, including discussion of the following medications: - Savella (milnacipran HCl) - Duloxetine hydrochloride (Cymbalta) - Pregabalin (Lyrica) -Gabapentin -Naltrexone

    1.5 general CEUs approved by OBNM

  • What to make of a positive ANA: recognizing lupus and related syndromes

    Presenter: Alena Guggenheim, ND
    Original Date: March 17, 2018

    This talk will cover clinical indications for ordering an Anti-nuclear Antibody test, as well as a review of optimal lab methodology. We will cover a clinical review of the following ANA positive diseases:
    • Systemic Lupus Erythematosus
    • Sjogrens
    • Scleroderma
    • Dermatomyositis
    • Polymyositis
    While the focus is on recognizing these disorders, will also discuss conventional and integrative approaches to treating these disorders.

    1.5 general CEUs approved by OBNM

  • The Ethics of Prescribing a Gluten-Free Diet

    Presenter: Lisa Shaver, ND
    Original Date: March 18.. 2018

    The gluten-free diet is a frequent staple in a practitioner’s list of modalities to use for a myriad of conditions. “Try a gluten-free diet” or “go gluten-free” has become a common phrase heard even between friends and neighbors, nutritionists and bloggers. However, a gluten-free diet (GFD) is a medical prescription for celiac disease. When prescribing a GFD prior to testing for celiac disease, a practitioner is unwittingly denying that patient a chance at revealing the root cause of symptoms and revealing a life-long/permanent systems-damaging autoimmune process with grave associated repercussions. We wouldn’t ask a non-type 1 diabetic to try insulin – it’s inappropriate. As conscientious practitioners, the medical community needs to be diagnosing celiac disease better and appropriately, or thoroughly ruling it out, prior to prescribing a GFD.
    Dr Shaver will present the top 10 reasons why prescribing a GFD is unethical in the absence of first performing thorough testing for celiac disease, from high risks of developing other unidentified autoimmune diseases to repercussions amid an entire family tree, to increase risks for cancers in celiacs who continue undiagnosed.

    2.0 ethics CEUs approved by OBNM

  • Low Dose Naltrexone & Autoimmune Conditions

    Presenter: Natalie Gustafson, PharmD
    Original Date: March 18, 2018

    Traditional naltrexone has been used to help patients struggling with addiction to opiates or alcohol. However, for decades we have recognized that at lower dosages, aptly named Low Dose Naltrexone (LDN), we see an entirely different effect on the body. LDN has been shown to have a significant impact on immune function and inflammation. It has been studied and used clinically in Multiple Sclerosis (MS), Crohn’s, Sjogren’s, Hashimoto’s, Lupus, Rheumatoid Arthritis and more. Understanding its mechanisms of action and analyzing literature as well as clinical practice can help practitioners ascertain which patients might benefit from LDN as part of their treatment protocol. There will be a short discussion of adjunctive compounded therapies used in these various conditions, such as biotin and methylcobalamin in MS, topicals for Sjogren’s and thyroid for Hashimoto’s.

    1.0 CEU approved by OBNM

  • IL-17, TNF, and Auto-Ab: To Thine Own Self Be True

    Presenter: Heather Zwickey, PhD
    Original Date: March 18, 2018

    A healthy immune system should be responsive to infectious disease and tolerant to self. As we gain a better understanding of how the immune system goes awry during autoimmune disease, we have discovered new mechanisms of self-tissue destruction. This presentation provides an update on three aspects of the immune system, and their role in autoimmunity.
    IL-17 is involved in the elimination of extra-cellular bacteria and fungi. However, IL-17 is also found in autoimmune lesions, suggesting that it can be pathogenic or beneficial depending upon the context. Likewise, while TNFalpha helps keep tumors at bay, it can be highly destructive in autoimmunity. Finally, we will examine the breadth of auto-antibodies to determine which are ubiquitous and which are truly predictive of disease. We will discuss the immunological chemicals as well as the pharmaceuticals – biologics – used to block these chemicals.

    1.5 pharmacy CEUs approved by OBNM
  • Autoimmune Thyroid and Pain: What’s the Connection?

    Presenter: Tyna Moore, ND, DC
    Original Date: March 18, 2018

    While autoimmune thyroid conditions are common. Few doctors understand or respect the intimate relationship between the condition and chronic pain. Common conditions that are treated as purely musculoskeletal conditions often have a hormonal component and often this link ultimately finds its root cause in autoimmune condition.
    Pharmaceutical interventions such as thyroid replacement hormone can often be a quick and effective treatment choice for many musculoskeletal conditions that could otherwise go on inappropriately diagnosed and treated as strictly biomechanics in nature.

    1.5 general CEUs approved by OBNM